Ronald Asbury Andrews
CIK 1299153 · Former CEO · last filed 2026-10-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OCX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
GALLATIN, TN 37066
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CNSY | Director | 1,843 | $1.57 | $2.9K | $0 | 1 | 2026-10-01 |
| PLUS THERAPEUTICS, INC. (PSTV) Delisted | Director | 922 | $3.87 | $3.6K | $0 | 2 | 2026-07-01 |
| PRPO | Director | 15,796 | $19.35 | $305.7K | $0 | 18 | 2026-01-20 |
| Insight Molecular Diagnostics Inc. (OCX) Delisted | Former CEO | 29,161 | $3.20 | $93.3K | $43.07M | 15 | 2022-12-09 |
| Oxford Immunotec Global PLC (OXFD) Delisted | Director | 4,081 | — | — | $0 | 6 | 2020-06-26 |
| LIFE | President, Medical Sciences | 0 | $42.30 | $0 | $154.8K | 7 | 2014-02-04 |
| CLARIENT, INC (CLRT) Delisted | Vice-Chairman and CEO | 0 | — | — | $53.0K | 7 | 2010-12-23 |
| Cardiac Science CORP (CSCX) Delisted | Director | 0 | — | — | $0 | 5 | 2010-12-06 |
Recent Filings · Page 2 of 7
62 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-17 | PRPO | Grant (A) | +1,510 | $10.0K | EDGAR |
| 2024-09-06 | PRPO | Mixed | — | $0 | EDGAR |
| 2024-07-16 | PRPO | Grant (A) | +2,157 | $10.0K | EDGAR |
| 2024-06-25 | PRPO | Grant (A) | — | $0 | EDGAR |
| 2024-04-17 | PRPO | Grant (A) | +3,153 | $21.0K | EDGAR |
| 2023-10-26 | PRPO | Grant (A) | +4,005 | $0 | EDGAR |
| 2023-09-14 | PRPO | Grant (A) | +6,060 | $0 | EDGAR |
| 2023-01-10 | PRPO | Grant (A) | — | $0 | EDGAR |
| 2022-12-09 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Mixed | +250,000 | $0 | EDGAR |
| 2022-08-18 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +40,000 | $38.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.